Diabetes
ADA/EASD Consensus Report | Management of Hyperglycemia in Type 2 Diabetes, 2022.
26 Sep, 2022 | 12:11h | UTCCommentary: ADA/EASD hyperglycemia management consensus update strengthens holistic care – medwire News
M-A | Association of gestational diabetes mellitus with cardiovascular and cerebrovascular diseases.
26 Sep, 2022 | 12:01h | UTCNews Release: Diabetes in pregnancy linked to risk of cardiovascular and cerebrovascular disease – BMJ Newsroom
Commentary on Twitter
Gestational diabetes mellitus is associated with increased risks of overall and type specific cardiovascular and cerebrovascular diseases that cannot be solely attributed to conventional cardiovascular risk factors or subsequent diabetes, finds new studyhttps://t.co/0fCIXKVK99
— The BMJ (@bmj_latest) September 22, 2022
Cohort Study | Modifiable risk factors may reduce the risk of type 2 diabetes in patients with a history of gestational diabetes.
23 Sep, 2022 | 13:08h | UTCNews Release: Healthy lifestyle linked to 90% lower risk of diabetes in susceptible women – BMJ Newsroom
Commentary on Twitter
Women with a history of diabetes in pregnancy can still reduce their chances of developing type 2 diabetes by adopting a healthy lifestyle, such as eating healthy, stopping smoking, exercising regularly, and not being overweight, finds new studyhttps://t.co/UkArl7ZyBS
— The BMJ (@bmj_latest) September 22, 2022
RCT | Insulin Glargine vs. Glimepiride vs. Sitagliptin vs. Liraglutide resulted in similar microvascular outcomes and death rates in patients with Type 2 diabetes not controlled with metformin.
22 Sep, 2022 | 13:20h | UTCGlycemia Reduction in Type 2 Diabetes — Microvascular and Cardiovascular Outcomes – New England Journal of Medicine (link to abstract – $ for full-text)
Related Study: Glycemia Reduction in Type 2 Diabetes — Glycemic Outcomes – New England Journal of Medicine
News Release: Two popular diabetes drugs outperformed others in large clinical trial – National Institutes of Health
Study shows that the leading causes of hospitalization of adults with diabetes are changing.
22 Sep, 2022 | 13:08h | UTCCommentaries:
The changing character of diabetes complications – The Lancet Diabetes & Endocrinology (free registration required)
Reasons for hospital admissions in people with type 2 diabetes are changing – MedicalXpress
RCT | Open-source automated insulin delivery in Type 1 Diabetes.
19 Sep, 2022 | 12:41h | UTCOpen-Source Automated Insulin Delivery in Type 1 Diabetes – New England Journal of Medicine (link to abstract – $ for full-text)
Video summary: Open-Source Automated Insulin Delivery in Type 1 Diabetes – NEJM
Commentaries:
Automated Insulin Delivery Ups Time in Target Glucose Range in T1D – HealthDay
Cohort Study | Patients diagnosed with diabetes by oral glucose tolerance test without elevated HbA1c had similar cardiovascular and renal disease risks as those without diabetes.
15 Sep, 2022 | 13:12h | UTC
Commentary on Twitter
#OriginalResearch: Oral glucose tolerance test diagnosed #diabetes were not confirmed by HbA1c during 4 year follow-up. Cases without HbA1c confirmation had similar vascular risk as the diabetes-free population. @whitehall2study @MikaKivimaki #AHAJournals https://t.co/ujC8cjRS7S pic.twitter.com/CRR3zlm5x2
— Circulation (@CircAHA) August 30, 2022
Consensus recommendations for the use of Automated Insulin Delivery (AID) technologies in clinical practice.
15 Sep, 2022 | 13:06h | UTC
USPSTF Statement | The current evidence is insufficient to recommend routine screening for prediabetes and type 2 diabetes in children and adolescents.
14 Sep, 2022 | 13:23h | UTCEditorials:
Recommendations for Screening Children and Adolescents for Prediabetes and Type 2 Diabetes – JAMA
Broader Screening for Youth-Onset Type 2 Diabetes—We Just Are Not There Yet – JAMA Network Open
Patient Page: Screening for Type 2 Diabetes in Children and Adolescents – JAMA
Author Interview: USPSTF Recommendation: Screening for Prediabetes and Diabetes in Children and Adolescents – JAMA
Cluster RCT | Tighter vs. less tight glycemic targets for women with gestational diabetes mellitus for reducing maternal and perinatal morbidity.
13 Sep, 2022 | 13:21h | UTC
RCT | In youths with new-onset type 1 diabetes, intensive glucose control for 24 months with a closed-loop system did not help to preserve pancreatic function.
11 Sep, 2022 | 22:57h | UTCClosed-Loop Therapy and Preservation of C-Peptide Secretion in Type 1 Diabetes – New England Journal of Medicine (link to abstract – $ for full-text)
Commentaries:
Preservation of C-Peptide Secretion Examined in Youth With T1D – HealthDay
Commentary on Twitter (video summary)
In patients with newly diagnosed type 1 diabetes, it is uncertain whether intensive glucose control can prevent the decline in endogenous insulin secretion. New research findings are summarized in a short video. https://t.co/gJeYus4G5z pic.twitter.com/igclSnyanu
— NEJM (@NEJM) September 10, 2022
A randomized crossover trial with 12 patients showed that a bihormonal “artificial pancreas” with closed-loop glucose control increases patients’ time on euglycemia after total pancreatectomy.
11 Sep, 2022 | 22:45h | UTCBihormonal Artificial Pancreas With Closed-Loop Glucose Control vs Current Diabetes Care After Total Pancreatectomy: A Randomized Clinical Trial – JAMA Surgery (free for a limited period)
Commentary: Novel Bihormonal Artificial Pancreas Beneficial After Pancreatectomy – HealthDay
Study shows bariatric surgery is more effective than lifestyle for type 2 diabetes remission.
8 Sep, 2022 | 14:27h | UTCNews Release: Bariatric surgery more effective than lifestyle for type 2 diabetes remission – Pennington Biomedical Research Center
Original Study: Diabetes Remission in the Alliance of Randomized Trials of Medicine Versus Metabolic Surgery in Type 2 Diabetes (ARMMS-T2D) – Diabetes Care
RCT | Advanced hybrid closed loop therapy versus conventional treatment in adults with type 1 diabetes.
7 Sep, 2022 | 12:30h | UTCAdvanced hybrid closed loop therapy versus conventional treatment in adults with type 1 diabetes (ADAPT): a randomised controlled study – The Lancet Endocrinology (link to abstract – $ for full-text)
Commentary: ‘Artificial Pancreas’ Best in Poorly Controlled Type 1 Diabetes – Medscape (free registration required)
Commentary on Twitter
New—Advanced hybrid closed loop therapy versus conventional treatment in adults with type 1 #diabetes (ADAPT): a randomised controlled study https://t.co/XrrmoDuQLy #T1D pic.twitter.com/GSLWA3xX7F
— The Lancet Diabetes & Endocrinology (@TheLancetEndo) September 2, 2022
RCT | The effect of a liberal approach to glucose control in critically ill patients with type 2 diabetes.
1 Sep, 2022 | 11:37h | UTCThe Effect of a Liberal Approach to Glucose Control in Critically Ill Patients with Type 2 Diabetes: A multicenter, parallel-group, open-label, randomized clinical trial – American Journal of Respiratory and Critical Care Medicine (link to abstract – $ for full-text)
Commentary from the author on Twitter
Excited to share results of the LUCID trial! A liberal approach to blood glucose targets reduced incidence hypoglycemia but did not improve patient-centered outcomes. https://t.co/HO53nzfBQT@MelbourneICU @CRENutrition @BellomoRinaldo @icurah @DogICUma @Eastwoodgm @MACHAustralia
— Alex Poole (@AlexPPoole) May 25, 2022
#ESCCongress – M-A | Patients with heart failure benefit from dapagliflozin regardless of ejection fraction.
30 Aug, 2022 | 12:14h | UTCNews Release: Patients with heart failure benefit from dapagliflozin regardless of ejection fraction – European Society of Cardiology
Related:
Case series of acute cholecystitis associated with the use of Glucagon-Like Peptide-1 Receptor agonists reported to the US Food and Drug Administration.
30 Aug, 2022 | 11:59h | UTCAcute Cholecystitis Associated With the Use of Glucagon-Like Peptide-1 Receptor Agonists Reported to the US Food and Drug Administration – JAMA Internal Medicine (free for a limited period)
#ESCCongress – RCT | Dapagliflozin reduced the risk of worsening heart failure or cardiovascular death in patients with heart failure with mildly reduced or preserved ejection fraction.
29 Aug, 2022 | 12:36h | UTCDapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction – New England Journal of Medicine (link to abstract – $ for full-text)
News Release: Dapagliflozin benefits patients with mildly reduced and preserved ejection fraction – European Society of Cardiology
Related (#ESCCongress 2021): RCT: SGLT2 inhibition reduced the combined risk of cardiovascular death or hospitalization in patients with heart failure and a preserved ejection fraction, regardless of the presence or absence of diabetes.
Commentary on Twitter
DELIVER: In an RCT involving patients with HF and a mildly reduced or preserved ejection fraction, dapagliflozin reduced the risk of the composite outcome of worsening heart failure or CV death. #ESCCongress https://t.co/0umSDn5HkO pic.twitter.com/nq7zD2Fi2K
— NEJM (@NEJM) August 27, 2022
Update on the management of diabetes in long-term care facilities.
26 Aug, 2022 | 13:23h | UTC
Randomized Crossover Trial | In patients with diabetic neuropathic pain, amitriptyline supplemented with pregabalin, pregabalin supplemented with amitriptyline, and duloxetine supplemented with pregabalin were similarly effective.
25 Aug, 2022 | 12:14h | UTC
Study Commentary | Is the evidence strong for spinal cord stimulation for diabetic neuropathy? Not all experts agree.
25 Aug, 2022 | 11:52h | UTCOriginal Study: RCT: Effect of High-frequency (10-kHz) Spinal Cord Stimulation in Patients With Painful Diabetic Neuropathy
Non-nutritive sweeteners affect human microbiomes and can alter glycemic responses.
24 Aug, 2022 | 14:17h | UTCNews Release: Non-nutritive sweeteners affect human microbiomes and can alter glycemic responses – Cell Press
Original Study: Personalized microbiome-driven effects of non-nutritive sweeteners on human glucose tolerance – Cell
Commentary on Twitter
The skinny on non-nutritive sweeteners (they are not inert) via a randomized trial & gut #microbiome assessment: impact is individualized and can impair glycemic responsehttps://t.co/B7CUPy7tMf @CellCellPress @SuezLab @EranElinav @segal_eran @WeizmannScience @Yot_Coh @Elinav_Lab pic.twitter.com/Jz7lUkWlNr
— Eric Topol (@EricTopol) August 19, 2022
Guideline | Management of adults with diabetes on dialysis.
23 Aug, 2022 | 13:16h | UTCManagement of adults with diabetes on dialysis – Joint British Diabetes Societies for Inpatient Care (PDF)
News Release: Latest JBDS dialysis guideline published – Diabetes Times
RCT | A lower glycemic criteria in not better than higher glycemic criteria for the diagnosis of gestational diabetes.
18 Aug, 2022 | 13:04h | UTCLower versus Higher Glycemic Criteria for Diagnosis of Gestational Diabetes – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: Pros and cons with lower vs higher threshold for gestational diabetes diagnosis – medwire News
Commentary on Twitter (thread – click for more)
1/ Overdiagnosis of Gestational Diabetes (GDM): New large randomized trial compared broader/narrower criteria -> NO improvement in mother/baby outcomes BUT x2 increase in % pregnant women labelled as GDM. Time to reconsider GDM testing – https://t.co/xrr0XrdhaZ
— Paul Glasziou (@PaulGlasziou) August 18, 2022
M-A of randomized trials | Effectiveness of exercise intervention during pregnancy on high-risk women for gestational diabetes mellitus prevention.
16 Aug, 2022 | 13:40h | UTC